Vivos Therapeutics, Inc.VVOS
Price (close)
$0.15
Market cap
—
P/E
—
Revenue (TTM)
$20.9M
Net income
-$25.5M
Dividend yield
—
1-year total return
-95.7%
Net margin
-121.8%
Revenue growth
45.2%
Debt / equity
—
What Vivos Therapeutics, Inc. does.
are a revenue stage medical technology and healthcare services company that features a comprehensive suite of proprietary
abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as mild to severe
obstructive sleep apnea (known as OSA) and snoring in adults. We call the use of our appliances coupled with specific therapeutic treatment protocols The Vivos Method.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Net income | -$12.1M | -$20.3M | -$23.8M | -$13.6M | -$11.1M | -$21.2M |
| Free cash flow | -$5.8M | -$18.1M | -$20.5M | -$12.7M | -$13.3M | -$17.6M |
More on VVOS.
- Vivos Therapeutics, Inc. summary
- Vivos Therapeutics, Inc. financial statements
- Vivos Therapeutics, Inc. key metrics
- Vivos Therapeutics, Inc. health scores and style box
- Vivos Therapeutics, Inc. earnings
- Vivos Therapeutics, Inc. dividends
- Vivos Therapeutics, Inc. valuation
- Vivos Therapeutics, Inc. ownership and insiders
- Vivos Therapeutics, Inc. peers
Figures from Vivos Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.